Abstract:AIM: To investigate fibroblast growth factor receptor 4 (FGFR4) protein expression in Chinese patients with resectable gastric cancer (GC) and the association with clinicopathological characteristics and survival. METHODS: One hundred and seventy-five GC patients who underwent curative surgical procedures were enrolled in this study. The protein expression of FGFR4 in formalin-fixed, paraffin-embedded (FFPE) GC tissues was determined by immunohistochemical (IHC) analysis. Patient clinicopathological data and survival information were also collected and. 2 statistical analysis was performed to analyze FGFR4 protein expression in the subgroups with differing clinicopathological characteristics including; gender, age, tumor location, differentiation, tumor-node-metastasis stage, macroscopic type, depth of invasion, lymph node metastases, distant metastasis, neural invasion and vascular invasion. Furthermore, some common molecular markers of GC in our cancer center, including p53, p27, topoisomerase. a (Topo. a) were also determined by IHC and their association with FGFR4 protein expression evaluated. The probability of survival for different subgroups with different clinicopathological characteristics was calculated using the Kaplan-Meier method and survival curves plotted using the log rank test. RESULTS: Seventy seven cases (44%) were found to have high expression of FGFR4 protein. Significantly different FGFR4 expression was observed between gastric cancers with differing expression of Topo II alpha (log rank chi(2) = 9.4760, P = 0.0236). No significant differences were observed between subgroups defined by any of the other clinicopathological characteristics. The median survival time of the FGFR4 high expression (77 cases) and low expression groups (98 cases) was 27 mo and 39 mo, respectively. The five-year survival rates and median survival times of gastric cancers with high FGFR4 expression were worse than those with low expression (30.8% vs 39.2%, 27 mo vs 39 mo), respectively, however, no significant difference was observed in survival time (log rank chi(2) = 1.0477, P = 0.3060). Survival analysis revealed that high expression of FGFR4 was a predictor of poor outcome in GC patients if the tumor was small (less than or equal to 3 cm in size) (log rank chi(2) = 5.5033, P = 0.0190), well differentiated (log rank chi(2) = 7.9757, P = 0.0047), and of T1 or T2 stage invasion depth (log rank chi(2) = 4.8827, P = 0.0271). CONCLUSION: Our results suggest that high tumor expression of FGFR4 protein is not an independent risk factor for GC cancer initiation, but is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or in the early stages of invasion.

Roles of single nucleotide polymorphism and loss of heterozygosity of FGFR4 gene in oncogenesis of gastric carcinoma

Relationship between forkhead box P3 gene polymorphisms and susceptibility to gastric cancer

Fibroblast Growth Factor Receptor 4 Gly388arg Polymorphism in Chinese Gastric Cancer Patients

The Fibroblast Growth Factor Receptor-4 Arg388 Allele is Associated with Gastric Cancer Progression.

Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer

[Correlation Between Gene Polymorphisms of Wnt Signalling Pathway Related Components and Risk of Gastric Carcinoma: a Case-Control Study].

Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.

Refined Mapping of Loss of Heterozygosity in Chinese Sporadic Gastric Carcinoma

Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer

Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer

The Correlations Between the Expression of Fgfr4 Protein and Clinicopathological Parameters As Well As Prognosis of Gastric Cancer Patients

Association between polymorphism in protooncogene FOS like antigen 1 and the susceptibility to gastric cancer

Association Between FGFR4 Gene Polymorphism and High-Risk HPV Infection Cervical Cancer

Expression of Tumor Related Gene NAG6 in Gastric Cancer and RFLP Analysis

Association Between CCND1 Rs9344 Polymorphism and Clinical Prognosis of Gastric Cancer

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

Expression of tumor related gene NAG6 in gastric cancer and restriction fragment length polymorphism analysis.

Genetic polymorphisms in folate-metabolizing genes associated with gastric cancer prognosis in northwest China subjects.

FGF/FGFR-related lncRNAs based classification predicts prognosis and guides therapy in gastric cancer

LRP5 Polymorphism-a Potential Predictor of the Clinical Outcome in Advanced Gastric Cancer Patients Treated with EOF Regimen.

Fibroblast Growth Factor Receptor 4 Regulates Proliferation and Antiapoptosis During Gastric Cancer Progression